Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory A Otterson

Showing results (91-100 of 157) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancerMiguel A Villalona-Calero, Paul Ritch, Jose A Figueroa, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2023
Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapyAndrew C Johns, Mike Yang, Lai Wei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2018
The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung CancerEric D Miller, James L Fisher, Karl E Haglund, et al.
Radiation Oncology (London, England)|October 7, 2018
Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer databaseEric D Miller, James L Fisher, Karl E Haglund, et al.
Cancer|April 19, 2016
Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancerLia M Halasz, Hajime Uno, Melissa Hughes, et al.
Plos One|June 19, 2008
HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cellsGuolin Chai, Lian Li, Wen Zhou, et al.
Cancer Chemotherapy and Pharmacology|January 29, 2010
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancerElaine T Lam, Jessie L-S Au, Gregory A Otterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871Lionel D Lewis, Antonius A Miller, Gary L Rosner, et al.
International Journal of Radiation Oncology, Biology, Physics|July 24, 2012
A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancerLudmila Katherine Martin, John Grecula, Guang Jia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 6, 2021
Crizotinib in Patients With MET-Amplified NSCLCD Ross Camidge, Gregory A Otterson, Jeffrey W Clark, et al.
Pageof 16

Showing results (91-100 of 157) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancerMiguel A Villalona-Calero, Paul Ritch, Jose A Figueroa, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2023
Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapyAndrew C Johns, Mike Yang, Lai Wei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2018
The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung CancerEric D Miller, James L Fisher, Karl E Haglund, et al.
Radiation Oncology (London, England)|October 7, 2018
Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer databaseEric D Miller, James L Fisher, Karl E Haglund, et al.
Cancer|April 19, 2016
Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancerLia M Halasz, Hajime Uno, Melissa Hughes, et al.
Plos One|June 19, 2008
HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cellsGuolin Chai, Lian Li, Wen Zhou, et al.
Cancer Chemotherapy and Pharmacology|January 29, 2010
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancerElaine T Lam, Jessie L-S Au, Gregory A Otterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871Lionel D Lewis, Antonius A Miller, Gary L Rosner, et al.
International Journal of Radiation Oncology, Biology, Physics|July 24, 2012
A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancerLudmila Katherine Martin, John Grecula, Guang Jia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 6, 2021
Crizotinib in Patients With MET-Amplified NSCLCD Ross Camidge, Gregory A Otterson, Jeffrey W Clark, et al.
Pageof 16